Click any tag below to further narrow down your results
Links
Boltz is launching a transformative approach to drug design and biological research by combining AI and open science, enabling over 100,000 scientists to innovate faster. With a newly raised $28 million seed round and a partnership with Pfizer, Boltz aims to break down barriers in drug development through open-source models and accessible computational tools.
- Boltz raised a $28 million seed round and partnered with Pfizer to advance open-source drug design models.
- Over 100,000 scientists are already using Boltz's tools, positioning it as a widely-adopted open-science alternative to closed AI drug discovery platforms.
- The core bet is that open-source, freely accessible AI models can accelerate biological research and drug development faster than proprietary approaches.